Large study shows “significantly higher risk” compared with “low-estrogen” pills
The FDA announced today that it has published a large retrospective study showing that women on birth control pills that contain drospirenone, an ingredient in Yaz, Yasmin, Ocella, and Beyaz, are approximately 75% more likely to have a blood clot than women on safer, established birth control pills.
Combined with the Danish study announced in the New York Times this week, there are now approximately 6 studies in recent years suggesting a higher risk of blood clots for birth control pills that contain drospirenone.
If you suffered a blood clot, pulmonary embolism, or stroke, while on Yaz, contact us to discuss your options for pursuing compensation, or have your questions answered by a qualified attorney, with no obligation. Lopez McHugh currently has a bellwether case being prepared for trial–it may be one of the first in the nation to be tried in the Yaz litigation.
Yaz contains a compound created by Bayer called drospirenone, a synthetic progestogen that may elevate the levels of potassium in the body. Side effects include heart attack, stroke, pulmonary embolism, blood clots, and even death.

Large study shows “significantly higher risk” compared with “low-estrogen” pills